Decreased CSF Aβ1-42 and increased CSF tau can differentiate symptomatic AD participants and cognitively normal individuals at high risk for symptomatic AD from cognitively normal individuals at low risk for symptomatic AD [69], [70]. The gene discussed is MAPT; the disease is Alzheimer disease.